Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 5/20 | 0.40 |
| ▸ | EP300 | Q09472 | 5/20 | 0.38 |
| ▸ | CCNC | P24863 | 2/20 | 0.38 |
| ▸ | CDK8 | P49336 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | BCL2 | P10415 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765952 | 0.97 | ELANE (0.41) | ELANEEP300CCNCCDK8F2 | |
| SCHEMBL30766039 | 0.91 | EP300 (0.44) | ELANEEP300CCNCCDK8F2 | |
| SCHEMBL23460649 | 0.89 | ELANE (0.47) | ELANEF2KDM4EALDH1A1 | |
| SCHEMBL30765501 | 0.84 | ELANE (0.44) | ELANEF2KDM4EALDH1A1EGLN1 | |
| SCHEMBL30765994 | 0.83 | ELANE (0.46) | ELANEF2KDM4EALDH1A1EGLN1 | |
| SCHEMBL23461187 | 0.81 | KDM4E (0.47) | ELANEF2KDM4ECASP1 | |
| SCHEMBL30765554 | 0.79 | KDM4E (0.44) | ELANEF2KDM4EALDH1A1CASP1 | |
| SCHEMBL23461184 | 0.79 | F2 (0.49) | F2ABCB1HPGDABCG2 | |
| SCHEMBL30765457 | 0.79 | ELANE (0.43) | ELANEF2KDM4EALDH1A1EGLN1 | |
| SCHEMBL30765773 | 0.78 | ELANE (0.41) | ELANEF2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |